Last reviewed 2026-06-03 · How we verify

placebo like amitriptyline

Tehran University of Medical Sciences · FDA-approved active Small molecule Under review Quality 1/100

placebo like amitriptyline is a Placebo Small molecule drug developed by Tehran University of Medical Sciences. It is currently FDA-approved for Clinical trial control for depression, anxiety, or chronic pain conditions (as comparator to amitriptyline).

This is a placebo formulation designed to mimic amitriptyline, a tricyclic antidepressant that blocks reuptake of norepinephrine and serotonin.

Amitriptyline, a serotonin transporter inhibitor, has been studied in clinical trials for various conditions, including Diarrhea-Predominant Irritable Bowel Syndrome, Quality of Life, Chronic Oral Food Refusal, and Quiescent Crohn's Disease. In these trials, amitriptyline was compared to a placebo-like intervention, such as a placebo-like version of the medication Mesalazine.

At a glance

Generic name	placebo like amitriptyline
Sponsor	Tehran University of Medical Sciences
Drug class	Placebo
Modality	Small molecule
Therapeutic area	Psychiatry / Neurology
Phase	FDA-approved

Mechanism of action

As a placebo comparator, this drug contains no active pharmaceutical ingredient but is formulated to resemble amitriptyline in appearance and administration. It is used in clinical trials to control for placebo effects when evaluating amitriptyline's therapeutic efficacy. The reference drug amitriptyline works by inhibiting the reuptake of norepinephrine and serotonin at neuronal synapses, thereby increasing their synaptic concentrations.

Approved indications

Clinical trial control for depression, anxiety, or chronic pain conditions (as comparator to amitriptyline)

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

placebo like amitriptyline CI brief — competitive landscape report
placebo like amitriptyline updates RSS · CI watch RSS
Tehran University of Medical Sciences portfolio CI

Frequently asked questions about placebo like amitriptyline

What is placebo like amitriptyline?

placebo like amitriptyline is a Placebo drug developed by Tehran University of Medical Sciences, indicated for Clinical trial control for depression, anxiety, or chronic pain conditions (as comparator to amitriptyline).

How does placebo like amitriptyline work?

This is a placebo formulation designed to mimic amitriptyline, a tricyclic antidepressant that blocks reuptake of norepinephrine and serotonin.

What is placebo like amitriptyline used for?

placebo like amitriptyline is indicated for Clinical trial control for depression, anxiety, or chronic pain conditions (as comparator to amitriptyline).

Who makes placebo like amitriptyline?

placebo like amitriptyline is developed and marketed by Tehran University of Medical Sciences (see full Tehran University of Medical Sciences pipeline at /company/tehran-university-of-medical-sciences).

What drug class is placebo like amitriptyline in?

placebo like amitriptyline belongs to the Placebo class. See all Placebo drugs at /class/placebo.

What development phase is placebo like amitriptyline in?

placebo like amitriptyline is FDA-approved (marketed).

Drug class: All Placebo drugs
Manufacturer: Tehran University of Medical Sciences — full pipeline
Therapeutic area: All drugs in Psychiatry / Neurology
Indication: Drugs for Clinical trial control for depression, anxiety, or chronic pain conditions (as comparator to amitriptyline)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing